Calypte und die Zeit nach AIDS2004 in Bangkok

Dr. Richard George, President and CEO of Calypte said, "We continue to execute our business plan and progress towards achieving our rapid test milestones. We are very appreciative of Marr's continued confidence and financial support for our company and together we look forward to the commercialization of Calypte's products."

Nach der Bekanntgabe der Ergebnisse wird Calypte explodieren da sind wir uns alle einig denke Ich..

Das es sich soo verzögert kann nur gutes bedeuten,ich denke sogar das etwas unerwartetes dazu kommt natürlich etwas positives in dem sinne...


Gruß

C.O  

viva la calyptia




HIV vaccine global partners strengthen collaboration to speed up progress

7 FEBRUARY 2005 | GENEVA -- As new developments in the search for an HIV vaccine take place, vaccine researchers from around the world are joining forces to accelerate progress towards an effective and safe HIV vaccine, with the full and equal involvement of countries most affected by the AIDS epidemic.

"With so many HIV vaccine clinical trials testing novel products ongoing and planned by a wide variety of investigators, it is time to intensify global collaboration. Lessons learned must benefit all working in this challenging, but advancing, field," said Dr Marie-Paule Kieny, Director, Initiative for Vaccine Research, World Health Organization (WHO).

About 50 experts from developing and industrialized countries presented and discussed their HIV vaccine research and development efforts at the first WHO-UNAIDS Meeting of Global Partners Promoting HIV Vaccine Research and Development, which took place in Montreux, Switzerland, on 2-3 February. The participating vaccine experts are from governments, academia, industry, public-private partnerships and non-governmental organizations throughout the world.

Recent progress in the HIV vaccine area includes the completion of several phase I and II trials of candidate vaccines. The publication last month of the Global HIV/AIDS Vaccine Enterprise Scientific Strategic Plan has also set a number of important milestones to be reached by all global partners.

But challenges remain. They include the need to increase clinical trial capacity worldwide and conduct trials at multiple sites against different globally prevalent HIV strains in populations with different transmission patterns; the appropriate use of trial sites for other HIV preventive research; the interface between HIV vaccine trials and increased access to anti-retroviral treatment; and the need to ensure that the most appropriate candidate vaccines are tested at the most appropriate sites regardless of who developed the product or strengthened the site.

"Overcoming these challenges will require intense international collaboration and coordination," said Dr Saladin Osmanov, Acting Coordinator, WHO-UNAIDS HIV Vaccine Initiative.

Twenty-five million people in sub-Saharan Africa are currently living with HIV, accounting for over 65% of all infections worldwide. Developing countries must be involved as equal partners in the development of HIV vaccines. An increasing number of trials are planned in African countries. This has not always been the case. Although the first clinical trial of an HIV vaccine took place in 1987 and more than 70 phase I HIV vaccine trials have since taken place, by 2003 only four phase I/II trials had been conducted on the African continent.

"Africa must participate in HIV vaccine development," said Dr Pascoal Mocumbi, High Representative, European and Developing Countries Clinical Trials Partnership and former Prime Minister of Mozambique. He added that the majority of African countries are more focused on disease control and very few have provisions for HIV vaccine research and development in their national AIDS programmes.

It is important to conduct vaccine trials in developing countries because the genetic variability of HIV may require testing of vaccine candidates in different areas of the world, where different strains are prevalent. It may also be necessary to evaluate how different infection routes, cofactors for HIV transmission, such as other sexually transmitted infections, and host genetic backgrounds influence vaccine-induced protection. Finally, licensing of a successful vaccine by regulatory bodies may require prior trials in countries with similar epidemiological settings.

The WHO-UNAIDS supported African AIDS Vaccine Programme (AAVP), established in 2000, is a network of African experts interacting with global partners and working together to promote and facilitate HIV vaccine research and evaluation in Africa, so that appropriate vaccines are developed and made accessible on this continent within the shortest possible timeframe. AAVP is developing a guidance document to assist countries in designing their national HIV vaccine plans.

Participants at the vaccine meeting addressed a number of policy issues including: the essential involvement of women and adolescents in clinical trials; ethics; access to and use of a future HIV vaccine; advocacy for increased vaccine science, education and funding; and broadening the involvement of the private sector in developing HIV vaccines. They recommended that a WHO-UNAIDS guidance document be developed, explaining how best to include women and adolescents in clinical trials of HIV vaccines.

This meeting of global HIV vaccine partners is expected to take place on a regular basis so major players in this field can share their experiences, ideas and devise ways to address challenges together.


RELATED LINKS

- UNAIDS
- HIV infections
For more information contact:


Ms Melinda Henry
Telephone: +41 22 791 2535
Mobile phone: +41 79 477 1738
Fax: +41 22 791 4858
E-mail: henrym@who.int

Ms Dominique de Santis
UNAIDS/London
Telephone: +41 22 791 4509
Mobile phone: +41 79 254 6803
E-mail: desantisd@unaids.org






Employment | Other UN Sites | Search | Suggestions | RSS | Privacy
© World Health Organization 2005. All rights reserved  


 

wäre doch wieder einmal zeit für so richtig geile news...  

sind news im anmarsch??  

I sent another e-mail about 20 mins ago 12;35 PST. to Tim this time with my home phone number as in past he respond quickly iwth in 5 mins. He informed me they do have more new financing in works with Marr and will change requiremnts on the 2 million note due in March.
I thru out a new financing figure of 9-15 million and he said somewhere in the middle of that number. That should see Calypte thru the end of the year. Marr has just given them 2 million to keep Calypte on tight fiscal budget.
China test results will not be out until after Chinese new year Celebrations end in about 15 days. Asked him about Fiscal year end and Qtr report with conference call he said should be expect in March.  

und Ihn fragen wie es aussieht .

Das hört sich verdammt komisch an, er hätte Tim seine Haustelefonnummer da gelassen er hätte Ihn zu Hause angerufen usw.  ; )

Naja Mal sehen was passiert...


Gruß

C.O  

02/08/05 22:02:16 0.35 0.34 0.35 17600
  02/08/05  22:02:18      0.35      0.34      0.36         0          §
  02/08/05  22:04:54      0.35      0.11     99.00         0          §
  02/08/05  22:06:41      0.35      0.34     99.00         0          §
  02/08/05  22:07:48      0.35      0.34     99.00         0          §
  02/08/05  22:11:57      0.35      0.34     99.00      7000          §
  02/08/05  22:13:04      0.35      0.34      0.37         0          §
  02/08/05  22:14:12      0.35      0.34      0.37 0

§
Broker: Schaun mer mal ;-)
 

 

Henan health authorities announced they will conduct HIV test on over 1.01 million people in 2005. Xinhua News Agency reported Henan health officials will provide free HIV-test to more than 630,000 people in 18 cities this year, including pregnant women, former commercial blood donors and other high risk groups. In addition, health officials will conduct routine HIV-test on an estimated 380,000 local women who are scheduled to get married or give birth this year.

Zhengzhou city reported the distribution of 200,000 free condoms in hotels, entertainment establishments and “places where homosexuals meet.” Officially, Henan has 11,844 confirmed HIV/AIDS cases, 2,026 children orphaned by AIDS. Henan province has a population of 93 million people.
––“Central China Provides Free AIDS Check-up for 1 million People,” Xinhua News Agency
 

The last three candlesticks formed a Bullish Morning Star Pattern . This is a bullish reversal pattern that marks a potential change in trend. Though it is highly reliable confirmation is still recommended.

http://www.americanbulls.com/...etTicker=AMEX%20%20%20%20%20%20&TYP=S

 

 http://www.stockta.com/cgi-bin/...symb=HIV&num1=3&cobrand=&mode=stock

heute geht es wieder runter, glaube nicht, dass bei sovielen widerständen etwas geht...  

Guys stop this nonsense! E-mail Tim with your homne hone number. Ask him regarding Test in China. He will tell you by phone or e-mail test results will not be out for about 15 days due to Chinese Holiday New year! Test results is no big deal they are fine just like anywhere else they been done you are making to much of the test results. He called me back within 5 mins yesterday of e-mailing him. ALso, most important in general terms I thru out financing and he said be "same guys" that will finance Calypte and will be good thru end of year. I thru out figure of 9-15 million and he said it would likely be somehwree in the middle of my number. So maybe 12 million.
 

 

laß mir doch meinen spaß...

es ist einfach schön, den einfältigen hier immer wieder die wahrheit vorzuhalten und zu sehen, wie sie sich winden, um an ihr vorbeizusehen....muhahahahahha  

                                       BID     ASK
  02.09.05  19:28:01      0.35      0.34      0.36          §
 

welche hattest du schon wieder... ach ja augrid!?  

profitieren... Auch Calypte !

Two studies call for more HIV tests
Rapid testing firms may see benefit
By Kristen Gerencher, MarketWatch
Last Update: 7:25 PM ET Feb. 9, 2005  


SAN FRANCISCO (MarketWatch) -- Shares of companies that make or distribute rapid HIV tests may get a boost from two studies that found expanding routine viral screening would be a cost-effective way to reduce transmission and improve public health.


Testing in areas where there's low prevalence of the virus that causes AIDS is affordable and prolongs the life of people carrying HIV without knowing it, according to a pair of studies to be published in the Feb. 10 edition of the New England Journal of Medicine.

Among the companies that may benefit are OraSure Technologies (OSUR: news, chart, profile) , which makes rapid HIV tests, and Abbott Laboratories (ABT: news, chart, profile) , which has a licensing agreement with OraSure.

The studies -- one from Duke University and the Veterans Affairs Palo Alto Health Care System, and the other from researchers at Harvard and Yale -- were conducted independently of each other but show similar results. Both sets of researchers are calling for doctors and policymakers to expand HIV counseling, testing and referrals, especially now that a diagnosis more often yields a chronic disease managed with cocktails of antiretroviral drugs rather than a death sentence.

"While the Centers for Disease Control and Prevention's guidelines are that routine screenings are effective in settings where there is a 1 percent or above prevalence of disease, our analysis showed that such screening at much lower prevalence levels would provide important benefits," said Dr. Gillian Sanders, lead author of the Duke and Palo Alto VA report, in a statement. "In addition, we found this screening would be cost-effective and in line with other commonly accepted screening programs."

A. David Paltiel, associate professor of health policy and administration at Yale and lead author of the second study, agreed.

"The publication of these papers represents a golden opportunity to jump-start the expansion of HIV testing services in the United States," he said in a statement.

 

Ist so schlecht nicht ...

;-)  

die umsätze sollten langsam aber sicher anziehen  

ein gewisser Dr. George sehr gute Kontakte zur CDC hat !
Hat Dr George nicht irgendetwas mit Calypte zu tun ;-)  

habe den namen auch schon gehört! *gg*  

Experts Urge Routine HIV Tests for All

Wed Feb 9, 5:11 PM ET Top Stories - AP


By LINDA A. JOHNSON, Associated Press Writer

Urging a major shift in U.S. policy, some health experts are recommending that virtually all Americans be tested routinely for the AIDS (news - web sites) virus, much as they are for cancer and other diseases.

Since the early years of the AIDS epidemic in the 1980s, the government has recommended screening only in big cities, where AIDS rates are high, and among members of high-risk groups, such as gay men and drug addicts.


But two large, federally funded studies found that the cost of routinely testing and treating nearly all adults would be outweighed by a reduction in new infections and the opportunity to start patients on drug cocktails early, when they work best.


"Given the availability of effective therapy and preventive measures, it is possible to improve care and perhaps influence the course of the epidemic through widespread, effective and cost-effective screening," Dr. Samuel A. Bozzette wrote in an editorial accompanying the studies, which appear in Thursday's New England Journal of Medicine (news - web sites).


A failure to institute such screening at doctors' offices and clinics would be "a critical disservice" to patients with the AIDS virus and "the future health of the nation," wrote Bozzette, who is from the University of California at San Diego and the Rand Corp. think tank in Santa Monica, Calif.


Dr. Robert Janssen, director of HIV (news - web sites)-AIDS prevention at the Centers for Disease Control and Prevention (news - web sites), said the CDC will re-evaluate its guidelines over the next two years, and will consider the study's findings as well as the availability of new, rapid HIV tests that produce results in a half-hour instead of the usual week or two.


Who would bear the cost of expanded testing — and the cost of the treatment, which runs to at least $15,000 a year — remains a sticky question amid government cutbacks in health-care funding. However, Janssen said the studies' findings could lead to some private insurers to encourage more HIV testing.


One of the studies, by researchers at Duke and Stanford universities and the Veterans Affairs Palo Alto Health Care System, estimated that routine one-time testing of everyone would cut new infections each year by just over 20 percent, and that every HIV-infected patient identified would gain an average of 1 1/2 years of life.


The other study, by Yale and Harvard researchers, found that testing people every three to five years would be cost-effective for all but the lowest-risk people, such as those who are celibate or are in monogamous heterosexual relationships. And even for those people, one-time testing was found to be cost-effective.


Nationwide, about 40,000 new HIV infections occur each year. An estimated 950,000 people are infected with the virus, but about 280,000 of them don't know it.


CDC guidelines recommend routine tests wherever the prevalence of HIV infection is more than 1 percent — basically, cities and some densely populated suburbs.


"If you need proof of the fact that it's not working, look at all the people who have slipped through the cracks — 280,000," said A. David Paltiel of the Yale School of Medicine's division of health policy, lead author of the second study.


The VA-funded study found that in areas where about 1 in 100 patients has undiagnosed HIV — what the CDC calls high-risk settings — widespread testing would cost about $15,100 for each year of good health gained by people diagnosed with the virus, counting the benefits to their sexual partners.


Even in areas with an undiagnosed HIV infection rate of only 1 in 2,000_ the rate in the general population — each healthy year gained by newly diagnosed HIV patients and their partners would still cost less than $50,000. That is the threshold at which health economists generally consider treatments to be cost-effective.


Paltiel noted the two groups of researchers had very similar cost-benefit results, even though they used different computer models.


"The cost-benefit to individuals and society is worth" widespread screening, said Dr. Lawrence Deyton, chief of public health in the Department of Veterans Affairs (news - web sites), which provides medical care to about 5 million veterans.


In light of the findings, he said the VA is going to urge more patients to get tested.





"We're going to take the ball and run with it," Deyton said.

 

 

02/10/05 16:40:34 0.38 0.37 0.38 129800
  02/10/05  16:45:11      0.38      0.37      0.38    122300          §
  02/10/05  16:45:21      0.38      0.37      0.38         0          §
  02/10/05  16:48:35      0.38      0.37      0.38      6000          §
  02/10/05  16:54:36      0.38      0.37      0.38     14000          §
  02/10/05  16:56:22      0.38      0.37      0.38      2000          §
  02/10/05  16:57:04      0.38      0.37      0.38      3400§
 

Sieht doch richtig gut aus !
RT 0,38

  02/10/05  16:40:34      0.38      0.37      0.38    129800          §
  02/10/05  16:45:11      0.38      0.37      0.38    122300          §
  02/10/05  16:45:21      0.38      0.37      0.38         0          §
  02/10/05  16:48:35      0.38      0.37      0.38      6000          §
  02/10/05  16:54:36      0.38      0.37      0.38     14000          §
  02/10/05  16:56:22      0.38      0.37      0.38      2000          §
  02/10/05  16:57:04      0.38      0.37      0.38      3400          §
  02/10/05  16:57:19      0.38      0.37      0.38       500          §
  02/10/05  16:59:25      0.38      0.37      0.39         0§